Online citations, reference lists, and bibliographies.
← Back to Search

Spastic Facial Muscle Disorders

Juwan Park, A. Harrison, M. Lee
Published 2012 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Facial muscles are a group of striated muscles that, among other things, control facial expression and are innervated by the facial nerve (CNVII). In contrast, the nearby eyelid retractor muscle and masticator muscles are innervated by the oculomotor (CNIII) and mandibular branch of trigeminal nerve (CNV), respectively.
This paper references
10.1111/j.1742-1241.2005.00603.x
Focal dystonia, with special reference to writer's cramp
N. Gordon (2005)
10.1097/00002341-199911000-00003
A novel mechanism for benign essential blepharospasm.
J. McCann (1999)
Practical handbook on botulinum toxin
D. Ranoux (2007)
10.3109/00016346409158189
Indications and Results
T. Malmström (1964)
10.1001/ARCHOPHT.1997.01100150633010
The role of blink adaptation in the pathophysiology of benign essential blepharospasm.
S. A. Hasan (1997)
10.1056/NEJMRA010032
Tourette's syndrome.
J. Jankovic (2001)
10.4102/SAJCD.V48I1.734
The swallowing and voicing characteristics of pharyngeal dystonia: a single case report.
L. Kahn (2001)
10.1007/BF00230437
Botulinum toxin paralysis of the orbicularis oculi muscle. Types and time course of alterations in muscle structúre physiology and lid kinematics
A. Horn (2004)
10.1136/JNNP.46.5.465
Hemifacial spasm: treatment by posterior fossa surgery.
P. Jannetta (1983)
10.1016/S0161-6420(86)33785-0
The use of botulinum toxin in the medical management of benign essential blepharospasm.
K. I. Perman (1986)
10.1046/J.1524-4725.2003.29120.X
Botulinum Toxin Type B (Myobloc)
L. Baumann (2003)
10.1212/01.WNL.0000027361.73814.0E
Blepharospasm: recent advances.
M. Hallett (2002)
10.1001/ARCHOPHT.1985.01050030043017
Botulinum A toxin injection as a treatment for blepharospasm.
A. Scott (1985)
10.1016/J.OPHTHA.2005.06.030
Modulation of sensory photophobia in essential blepharospasm with chromatic lenses.
Natasha L Herz (2005)
10.1212/WNL.58.12.1843
Botulinum toxin improves lid opening delays in blepharospasm-associated apraxia of lid opening
R. Forget (2002)
10.1097/00002341-200211000-00010
Skin Cooling Before Periocular Botulinum Toxin A Injection
J. S. Linder (2002)
10.1002/MDS.870030209
Meige syndrome: Neuropathology of a case
J. Kulisevsky (1988)
10.4088/JCP.V61N0210
Clozapine in the treatment of neuroleptic-induced blepharospasm: a report of 4 cases.
H. Levin (2000)
10.1016/S0002-9394(98)00099-3
Spontaneous remission in patients with essential blepharospasm and Meige syndrome.
A. Castelbuono (1998)
10.1097/00002341-199809000-00002
Blepharospasm: Past, Present, and Future
R. Anderson (1998)
10.1002/MDS.870040402
Eyelid movement abnormalities in progressive supranuclear palsy
Lawrence I. Golbe (1989)
10.1097/01.IOP.0000065203.88182.CF
Benign Essential Blepharospasm Among Residents of Olmsted County, Minnesota, 1976 to 1995: An Epidemiologic Study
E. Bradley (2003)
10.1212/WNL.46.1.26
Botulinum toxin therapy, immunologic resistance, and problems with available materials
G. Borodic (1996)
10.1111/j.1468-1331.2010.03058.x
Botulinum toxin for treatment of dystonia
D. Dressler (2010)
10.1002/MDS.870060309
Dystonic tics in patients with Tourette's syndrome
J. Jankovic (1991)
10.1227/01.NEU.0000065129.25359.EE
Microvascular Decompression Surgery in the United States, 1996 to 2000: Mortality Rates, Morbidity Rates, and the Effects of Hospital and Surgeon Volumes
S. Kalkanis (2003)
10.1097/00041327-199506000-00006
A Controlled Trial of Regional Sympatholysis in the Treatment of Photo‐oculodynia Syndrome
P. Fine (1995)
10.1212/WNL.55.1.155
A case-controlled MRI/MRA study of neurovascular contact in hemifacial spasm.
E. Tan (2000)
10.1097/00002341-200107000-00007
Differential Section of the Seventh Nerve as a Tertiary Procedure for the Treatment of Benign Essential Blepharospasm
R. Fante (2001)
10.1111/j.1600-0404.1996.tb07053.x
Botulinum toxin A injection in the treatment of hemifacial spasm
R. S. Chen (1996)
10.1016/S0161-6420(97)30220-6
Blepharospasm and hemifacial spasm. Randomized trial to determine the most appropriate location for botulinum toxin injections.
J. Price (1997)
10.1212/WNL.46.2.476
Blepharospasm in association with a lower pontine lesion
M. Aramideh (1996)
10.1046/J.1524-4725.2003.29123.X
Botulinum Toxin Type B for Dynamic Glabellar Rhytides Refractory to Botulinum Toxin Type A
T. Alster (2003)
10.1159/000066186
Anesthesia with EMLA® Cream for Botulinum A Toxin Injection into Eyelids
M. Söylev (2002)
10.3109/01658109209058127
'Ping-pong' gaze
Borodic Ge (1992)
Laryngeal dystonia (spasmodic dysphonia): observations of 901 patients and treatment with botulinum toxin.
M. Brin (1998)
10.1176/JNP.2008.20.2.241
Neuroleptic Induced Laryngo-Pharyngeal Dystonia
Narendrakumar Alappan (2008)
10.1016/S0161-6420(95)30757-9
Long-term changes in duration of relief with botulinum toxin treatment of essential blepharospasm and hemifacial spasm.
J. Ainsworth (1995)
10.1016/S0161-6420(91)32288-7
Clinical doxorubicin chemomyectomy. An experimental treatment for benign essential blepharospasm and hemifacial spasm.
J. Wirtschafter (1991)
10.1002/MDS.870020303
Blepharospasm and autoimmune diseases
J. Jankovic (1987)
10.1136/jnnp.65.1.111
Botulinum toxin treatment of synkinesia and hyperlacrimation after facial palsy
B. Boroojerdi (1998)
10.1016/S0161-6420(87)33458-X
Hemifacial spasm. Results of unilateral myectomy.
P. Garland (1987)
10.1136/BJO.80.12.1073
Treatment selections of 239 patients with blepharospasm and Meige syndrome over 11 years.
J. Mauriello (1996)
10.1002/mds.10314
Familial blepharospasm is inherited as an autosomal dominant trait and relates to a novel unassigned gene
G. Defazio (2003)
10.3171/JNS.1977.47.3.0321
Etiology and definitive microsurgical treatment of hemifacial spasm. Operative techniques and results in 47 patients.
P. Jannetta (1977)
10.1016/j.toxicon.2009.03.010
Xeomin is free from complexing proteins.
J. Frevert (2009)
10.3928/1542-8877-19900501-07
Apraxia of lid opening in blepharospasm.
D. Jordan (1990)
10.1016/S0025-6196(12)64977-5
Treatment of blepharospasm with botulinum toxin.
R. H. Kennedy (1989)
10.1002/MDS.870100425
Botulinum a toxin for the so‐called apraxia of lid opening
V. Lepore (1995)
10.1067/MJD.2000.105567
Pharmacology of botulinum toxin.
W. Huang (2000)
10.1007/s00381-002-0604-1
Functional anatomy of thalamus and basal ganglia
M. Herrero (2002)
10.1212/WNL.48.4.1107
Post‐irradiation neuromyotonia in bilateral facial and trigeminal nerve distribution
J. Martí-Fàbregas (1997)
10.1152/JN.1997.77.5.2842
Animal model explains the origins of the cranial dystonia benign essential blepharospasm.
E. J. Schicatano (1997)
10.1002/MDS.870090605
“Apraxia of lid opening,” a focal eyelid dystonia: Clinical study of 32 patients
P. Krack (1994)
10.1002/MDS.870090216
Development of resistance to botulinum toxin type A in patients with torticollis
P. Greene (1994)
Acquired blepharoptosis secondary to essential blepharospasm.
F. S. Bodker (1993)
10.1016/S0733-8635(02)00043-8
Update on botulinum toxin for facial aesthetics.
J. Cather (2002)
10.1016/S0002-9394(14)74794-4
Effects of eyelid protractor excision for the treatment of benign essential blepharospasm.
B. Frueh (1992)
10.1016/S0161-6420(88)32977-5
Long-term results and complications of botulinum A toxin in the treatment of blepharospasm.
J. Dutton (1988)
10.1002/ANA.410320404
Hemifacial spasm: Evaluation by magnetic resonance imaging and magnetic resonance tomographic angiography
C. Adler (1992)
10.1016/S0025-6196(11)63621-5
Hemifacial spasm and other craniofacial movement disorders.
V. Evidente (1998)
Motor nerve sprouting in human orbicularis muscle after botulinum A injection.
J. Holds (1990)
10.1001/jama.2010.1937
Terminology for preparations of botulinum neurotoxins: what a difference a name makes.
A. Albanese (2011)
10.1007/s10384-005-0198-8
Correlation of Low-T3 Syndrome with Blepharospasm and Hemifacial Spasm
Nami Nishikiori (2005)
10.1097/00041327-199806000-00016
Drug‐Associated Facial Dyskinesias—A Study of 238 Patients
J. Mauriello (1998)
10.1212/WNL.50.2.485
Skeletal muscle‐specific immunotoxin for the treatment of focal muscle spasm
J. Hott (1998)
10.1212/WNL.43.4.834
Longitudinal experience with botulinum toxin injections for treatment of blepharospasm and cervical dystonia
J. Jankovic (1993)
10.1212/WNL.37.4.616
Botulinum A toxin for cranial‐cervical dystonia
J. Jankovic (1987)
10.1212/WNL.57.6.1013
Prolonged orbicularis oculi activity
V. Tozlovanu (2001)
10.3928/1542-8877-19900501-08
Side effects of the use of botulinum toxin for treatment of benign essential blepharospasm and hemifacial spasm.
H. K. Kalra (1990)
10.1136/jnnp.72.4.459
Respective potencies of Botox and Dysport: a double blind, randomised, crossover study in cervical dystonia
D. Ranoux (2002)
Medico-legal reports.
McCormack Mp (1993)
10.1001/ARCHNEUR.1994.00540230053012
The lesion causing continuous facial myokymia in multiple sclerosis.
L. Jacobs (1994)
10.1074/jbc.M703446200
A Novel Subunit Structure of Clostridium botulinum Serotype D Toxin Complex with Three Extended Arms*
K. Hasegawa (2007)
10.3171/JNS.1997.86.4.0654
Electrophysiological investigation of hemifacial spasm after microvascular decompression: F waves of the facial muscles, blink reflexes, and abnormal muscle responses
M. Ishikawa (1997)
10.1001/ARCHOTOL.125.6.627
Long-term enhancement of botulinum toxin injections by upper-eyelid surgery in 14 patients with facial dyskinesias.
J. Mauriello (1999)
10.1136/jnnp.2005.068007
A family study on primary blepharospasm
G. Defazio (2006)
10.1097/00055735-199510000-00014
Blepharospasm and related facial movement disorders
B. Patel (1995)
10.1111/j.1468-1331.2009.02877.x
Routine use of Xeomin® in patients previously treated with Botox®: long term results
D. Dressler (2009)
10.1080/09638280701568296
Pharmacology of therapeutic botulinum toxin preparations
D. Dressler (2007)
10.1002/mds.1275
Epidemiology of primary blepharospasm
G. Defazio (2002)
10.1016/S0022-3999(99)00105-1
Psychiatric disorders in patients with blepharospasm - a reactive pattern?
T. Wenzel (2000)
10.1167/iovs.10-6427
Modulating neuromuscular junction density changes in botulinum toxin-treated orbicularis oculi muscle.
A. Harrison (2011)
10.1016/S0161-6420(98)93484-4
Long-term efficacy of local doxorubicin chemomyectomy in patients with blepharospasm and hemifacial spasm.
J. Wirtschafter (1998)
10.1016/S1091-8531(03)00056-9
Extraocular muscle force generation after ricin-mAb35 injection: implications for strabismus treatment.
S. Christiansen (2003)
10.1016/J.SURVOPHTHAL.2006.10.003
Botulinum toxin in ophthalmology.
J. Dutton (2007)
10.1007/BF00839203
The management of blepharospasm and hemifacial spasm
J. Elston (2004)
10.1001/JAMA.1982.03330230060037
Blinking and blepharospasm. Mechanism, diagnosis, and management.
J. Jankovic (1982)
10.1097/00005053-198412000-00009
Psychological Aspects of Essential Blepharospasm
E. L. Diamond (1984)
10.2165/00003495-200767050-00003
Botulinum Neurotoxin Type A Free of Complexing Proteins (XEOMIN®) in Focal Dystonia
W. Jost (2012)
10.1080/01480540701375091
Skeletal Muscle Atrophy Induced by Intramuscular Repeated Dose of Botulinum Toxin Type A in Rats
W. H. Choi (2007)
10.1016/J.AJO.2006.02.020
The evaluation of light sensitivity in benign essential blepharospasm.
W. Adams (2006)
10.1111/J.1365-2273.1996.TB01018.X
Treatment of facial synkinesis and facial asymmetry with botulinum toxin type A following facial nerve palsy.
M. W. Armstrong (1996)
10.1007/BF00839205
Clostridium botulinum toxins: a general review of involvement in disease, structure, mode of action and preparation for clinical use
P. Hambleton (2004)
10.1001/ARCHOPHT.1984.01040030216030
Treatment of essential blepharospasm. I. Comparison of facial nerve avulsion and eyebrow-eyelid muscle stripping procedure.
C. McCord (1984)
10.1001/ARCHOPHT.1984.01040031184014
Treatment of blepharospasm with botulinum toxin. A preliminary report.
B. Frueh (1984)
10.1007/BF00874096
Spasmodic laryngeal dyspnea: a rare manifestation of laryngeal dystonia
P. Zwirner (2004)
10.1212/WNL.41.11.1800
Botulinum‐induced alteration of nerve‐muscle interactions in the human orbicularis oculi following treatment for blepharospasm
K. Alderson (1991)
[Treatment of essential blepharospasm].
E. Gugg (1990)
10.1097/00041327-199412000-00004
Chemomyectomy of the Orbicularis Oculi Muscles for the Treatment of Localized Hemifacial Spasm
J. Wirtschafter (1994)
10.1097/00041327-200412000-00003
Chronic Myokymia Limited to the Eyelid Is a Benign Condition
R. Banik (2004)
10.1136/jnnp.59.3.309
Pretarsal application of botulinum toxin for treatment of blepharospasm.
M. Aramideh (1995)
10.1016/S0002-9394(14)76386-X
The effect of omitting botulinum toxin from the lower eyelid in blepharospasm treatment.
B. Frueh (1988)
Blinking and blepharospasm.
T. Dening (1988)
10.1007/s00415-006-7003-6
Dystonia in Parkinson’s disease
E. Tolosa (2006)
Botulinum A toxin therapy in ophthalmology: a report of patients with facial dystonias.
I. Vissenberg (1993)
10.1001/ARCHNEUR.59.3.418
Botulinum toxin A treatment for primary hemifacial spasm: a 10-year multicenter study.
G. Defazio (2002)
10.1016/S0002-9394(14)76994-6
Botulinum toxin injections in the treatment of seventh nerve misdirection.
A. Putterman (1990)
10.1016/S0161-6420(87)33338-X
Effectiveness of botulinum toxin therapy for essential blepharospasm.
P. Engstrom (1987)
10.1111/J.1442-9071.1994.TB00793.X
Efficacy and side effects of botulinum toxin treatment for blepharospasm and hemifacial spasm.
J. Price (1994)
Doxil-induced chemomyectomy: effectiveness for permanent removal of orbicularis oculi muscle in monkey eyelid.
L. McLoon (2001)
10.1016/S0161-6420(93)31384-9
Serum antibody production to botulinum A toxin.
R. Siatkowski (1993)
10.1016/0140-6736(90)90263-5
Dose standardisation of botulinum toxin
E. Schantz (1990)
10.1016/S0033-3182(78)70921-7
Blepharospasm: organic or functional?
J. Cavenar (1978)
10.1159/000116969
Genetic contribution to idiopathic adult-onset blepharospasm and cranial-cervical dystonia.
G. Defazio (1993)
10.1136/bjo.71.9.664
Long-term results of treatment of idiopathic blepharospasm with botulinum toxin injections.
J. Elston (1987)
10.1136/jnnp.64.1.6
A double blind, randomised, parallel group study to investigate the dose equivalence of Dysport® and Botox®in the treatment of cervical dystonia
T. Odergren (1998)
10.1159/000064953
Clinical Features of Antibody-Induced Complete Secondary Failure of Botulinum Toxin Therapy
D. Dressler (2002)
10.1002/MDS.870050121
Opioid therapy in the movement disorders.
A. Walters (1990)
10.1001/ARCHOPHT.1965.00970030157003
APRAXIA OF LID OPENING.
J. Goldstein (1965)
10.1136/BJO.73.10.856
Advances in Ophthalmic Plastic and Reconstructive Surgery
A. McNab (1989)
[Treatments by local injections of botulinum toxin in neurology. Indications and results].
S. Soulayrol (1993)
10.1212/WNL.49.1.223
Maladaptive neural compensatory mechanisms in Bell's palsy-induced blepharospasm
R. Baker (1997)
10.1136/jnnp.51.6.767
Blepharospasm: a review of 264 patients.
F. Grandas (1988)
10.1016/0039-6257(91)90207-V
Botulinum A toxin (Oculinum) in ophthalmology.
M. Osako (1991)
10.1212/WNL.56.11.1579
Prevalence of primary blepharospasm in a community of Puglia region, Southern Italy
G. Defazio (2001)
10.2147/OPTH.S13978
Profile of Xeomin® (incobotulinumtoxinA) for the treatment of blepharospasm
J. Park (2011)
10.1212/01.WNL.0000055087.96356.BB
Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia
J. Jankovic (2003)
10.1016/S0002-9394(02)01387-9
Hemifacial spasm caused by vertebral artery dolichoectasia.
E. A. Rahman (2002)
10.1017/S0317167100027748
Botulinum toxin injections in the treatment of blepharospasm, hemifacial spasm, and eyelid fasciculations.
S. Kraft (1988)
10.1001/ARCHOPHT.1981.03930011056015
Blepharospasm surgery. An anatomical approach.
W. Gillum (1981)
10.1097/00055735-200310000-00003
Chemodenervation for facial dystonias and wrinkles
A. Harrison (2003)
10.1007/s004150070100
Complete secondary botulinum toxin therapy failure in blepharospasm
D. Dressler (2000)
10.1016/S0002-9394(14)77954-1
The use of botulinum toxin in blepharospasm.
N. Shorr (1985)
10.1111/j.1468-1331.2009.02880.x
Clinical efficacy and tolerability of Xeomin® in the treatment of blepharospasm
J. Jankovic (2009)
10.1136/jnnp.49.7.827
Botulinum toxin treatment of hemifacial spasm.
J. Elston (1986)
Diagnosis and classification of tics and Tourette syndrome.
J. Jankovic (1992)
10.1016/J.CLINDERMATOL.2003.11.002
Type A botulinum toxin in the upper aspect of the face.
D. Hexsel (2003)
10.3928/0191-3913-19970701-10
Diplopia following subcutaneous injections of botulinum A toxin for facial spasms.
S. Wutthiphan (1997)
10.3346/JKMS.1993.8.5.334
Botulinum a toxin treatment of hemifacial spasm and blepharospasm.
Y. C. Park (1993)
10.1093/OXFORDJOURNALS.BRAIN.A101863
Memory-contingent saccades and the substantia nigra postulate for essential blepharospasm.
J. Hotson (1991)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar